--- title: "Pfizer’s Hympavzi secures FDA expanded indications for haemophilia" type: "News" locale: "en" url: "https://longbridge.com/en/news/289169446.md" description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser." datetime: "2026-06-09T09:05:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289169446.md) - [en](https://longbridge.com/en/news/289169446.md) - [zh-HK](https://longbridge.com/zh-HK/news/289169446.md) --- # Pfizer’s Hympavzi secures FDA expanded indications for haemophilia A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser. ### Related Stocks - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) ## Related News & Research - [Cerity Partners LLC Buys 1,448,806 Shares of Pfizer Inc. $PFE](https://longbridge.com/en/news/289292675.md) - [](https://longbridge.com/en/news/288873963.md) - [Pfizer Says FDA Approves Expanded HYMPAVZI Indication For Hemophilia A And B](https://longbridge.com/en/news/289046752.md) - [Shift in biosimilar commercial landscape essential for sector sustainability, expert says](https://longbridge.com/en/news/289174897.md) - [Parabilis eyes $475m IPO to push lead asset into Phase III](https://longbridge.com/en/news/288850252.md)